Rapid Clinical Remission With Upadacitinib in a Pediatric Patient With Refractory Crohn's Disease

Inflamm Bowel Dis. 2023 Jul 5;29(7):1175-1176. doi: 10.1093/ibd/izad048.
No abstract available

Keywords: Crohn’s disease; JAK inhibitor; inflammatory bowel disease; pediatric; upadacitinib.

Plain language summary

A pediatric patient with Crohn’s disease refractory to anti-tumor necrosis factor therapy, vedolizumab, ustekinumab, and 6-mercaptopurine achieved rapid clinical remission with upadacitinib. This is the first report of successful use of upadacitinib in pediatric inflammatory bowel disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Crohn Disease* / drug therapy
  • Heterocyclic Compounds, 3-Ring / therapeutic use
  • Humans
  • Immunosuppressive Agents
  • Remission Induction
  • Treatment Outcome
  • Ustekinumab

Substances

  • upadacitinib
  • Heterocyclic Compounds, 3-Ring
  • Immunosuppressive Agents
  • Ustekinumab